SWISS MEDENDI SA

Safe chemotherapy infusion

Swiss Medendi is the only company to offer a specific, disposable, patent granted medical device for a safe chemotherapy infusion. HC100 protects patient’s vessels from chemical phlebitis, sclerosis and necrosis. It reduces and or eliminates injuries and complications associated with today’s devices. No other specific technology is available neither efficient as our in a close and sterile system. There are no variations to chemotherapy protocols, and end users such as hospitals, GPOs and Medical practices, may save over 77% of their costs comparing with today’s methods and devices, we are bringing patient’s quality of life to levels never seen before.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
Milestone

01.07.2020

CP Start-up Incubation

No Jobs

No videos and documents

W.A. de Vigier Stiftung

Seit 1987 fördert die W.A. de Vigier Stiftung zukunftweisende Geschäftsideen mit einem Förderpreis von je 5 x CHF 100'000. Nebst diesem Startkapital erhalten die Preisträger auch immaterielle Unterstützung; etwa in Form von wertvollen Kontakten, Medientrainings sowie Präsenz in Presse, TV und Radio. W.A. de Vigier Stiftung versteht ihr Engagement als Beitrag zu einer wettbewerbsstarken und gesunden Schweizer Wirtschaft.

Website

SWISS MEDENDI SA

Safe chemotherapy infusion

Headquarter:
Lugano

Foundation Date:
December 2012

Technology:

  • Medtech

Sectors:

  • Cancer
  • Medical devices
  • Medtech